Oscar Health, Inc.
Oscar Health, Inc. (OSCR) Financial Performance & Income Statement Overview
Explore the financials of Oscar Health, Inc. (OSCR), including yearly and quarterly data on income, cash flow, and balance sheets.
Oscar Health, Inc. (OSCR) Income Statement & Financial Overview
Review Oscar Health, Inc. OSCR income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $3.05B | $2.39B | $2.42B | $2.22B |
| Cost of Revenue | $0.00 | $1.00 | $0.00 | $0.00 |
| Gross Profit | $3.05B | $2.39B | $2.42B | $2.22B |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $482.76M | $466.58M | $459.52M | $435.14M |
| Operating Expenses | $2.76B | $2.55B | $2.48B | $2.16B |
| Total Costs & Expenses | $2.76B | $2.55B | $2.48B | $2.16B |
| Interest Income | $0.00 | $0.00 | $1.55M | $0.00 |
| Interest Expense | $5.99M | $6.03M | $5.82M | $5.99M |
| Depreciation & Amortization | $6.73M | $9.23M | $7.50M | $7.60M |
| EBITDA | $300.94M | -$138.43M | -$39.00M | $74.54M |
| EBITDA Ratio | $0.10 | -$0.06 | -$0.02 | $0.03 |
| Operating Income | $288.21M | -$153.69M | -$52.31M | $60.95M |
| Operating Income Ratio | $0.09 | -$0.06 | -$0.02 | $0.03 |
| Other Income/Expenses (Net) | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Before Tax | $288.21M | -$153.69M | -$52.31M | $60.95M |
| Income Before Tax Ratio | $0.09 | -$0.06 | -$0.02 | $0.03 |
| Income Tax Expense | $12.71M | -$404000.00 | $2.08M | $4.64M |
| Net Income | $275.27M | -$153.55M | -$54.60M | $56.21M |
| Net Income Ratio | $0.09 | -$0.06 | -$0.02 | $0.03 |
| EPS | $1.10 | -$0.62 | -$0.22 | $0.24 |
| Diluted EPS | $0.92 | -$0.62 | -$0.22 | $0.18 |
| Weighted Avg Shares Outstanding | $251.28M | $240.39M | $243.11M | $238.67M |
| Weighted Avg Shares Outstanding (Diluted) | $305.94M | $265.85M | $243.11M | $303.96M |
The company's financials show resilient growth, with revenue advancing from $2.22B in Q2 2024 to $3.05B in Q1 2025. Gross profit remained healthy with margins at 100% in Q1 2025 compared to 100% in Q2 2024. Operating income hit $288.21M last quarter, sustaining a consistent 9% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $300.94M. Net income rose to $275.27M, while earnings per share reached $1.10. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan